Patent 11752154 was granted and assigned to PTC Therapeutics on September, 2023 by the United States Patent and Trademark Office.
The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and/or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.